“The present predicament has uncovered some structural weaknesses inside the EU’s medicines provide chain as well as a superior dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides reported. She advised that provide chain troubles be tackled within an EU pharmaceutical method predicted being launched